^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tovetumab (MEDI-575)

    i
    Other names: Anti-PDGFRa mAb, MEDI-575
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    PDGFR α inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1b/2, N=99, Terminated, MedImmune LLC | Phase classification: P1/2 --> P1b/2 | Completed --> Terminated; In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to safety concerns.
    Clinical • Phase classification • Trial termination • Combination therapy
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA expression
    |
    carboplatin • paclitaxel • tovetumab (MEDI-575)